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INTRODUCTION
Autophagy is an essential, evolutionarily conserved 
process that degrades protein aggregates and damaged 
organelles in order to maintain cytoplasmic homeostasis [1]. 
It begins with the sequestration of cytoplasmic constituents 
in double-membrane vesicles, called autophagosomes. The 
vesicles then fuse with lysosomes to form autolysosomes, 
where the engulfed contents undergo degradation and 
recycling to sustain cellular metabolism [2].
In normal cells, autophagy is generally considered 
as a cytoprotective mechanism [1]. However, the 
roles of autophagy in cancer cells are paradoxical and 
controversial. Autophagy acts both as a tumor suppressor 
that prevents tumor initiation and as a protector of cancer 
cell survival that removes damaged organelles under 
stress conditions [3, 4]. The outcome of autophagy 
regulation in cancer cells may vary depending on the 
types of cancers, individual characteristics of cancer cells, 
microenvironments, and therapeutic treatments [5, 6]. 
Identification of novel small molecule Beclin 1 mimetics activating 
autophagy
Jia Yu1,2,*, Lan Lan2,*, Seth J. Lewin2, Steven A. Rogers3, Anuradha Roy4, Xiaoqing 
Wu2, Philip Gao5, John Karanicolas2,6, Jeffrey Aubé3,7, Baiwang Sun1 and Liang Xu2
1School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, China
2Department of Molecular Biosciences, The University of Kansas, Lawrence, Kansas 66045, USA
3Center of Biomedical Research Excellence, The University of Kansas, Lawrence, Kansas 66045, USA
4High Throughput Screening Laboratory, The University of Kansas, Lawrence, Kansas 66045, USA
5COBRE-PSF Protein Production Group, The University of Kansas, Lawrence, Kansas 66045, USA
6Center for Bioinformatics, The University of Kansas, Lawrence, Kansas 66045, USA
7Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, USA
*These authors contributed equally to this work
Correspondence to: Liang Xu, email: xul@ku.edu 
Baiwang Sun, email: chmsunbw@seu.edu.cn
Keywords: Beclin 1 mimetics, autophagy, Bcl-xL protein, cancer, high-throughput screen
Received: March 26, 2017    Accepted: May 06, 2017    Published: May 18, 2017
Copyright: Yu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Anti-apoptotic proteins Bcl-2 and Bcl-xL could block autophagy by binding to 
Beclin 1 protein, an essential inducer of autophagy. Compounds mimicking Beclin 
1 might be able to disrupt Bcl-xL/2-Beclin 1 interaction, free out Beclin 1, and 
thus trigger autophagy. In order to identify small molecule Beclin 1 mimetics, a 
fluorescence polarization-based high-throughput screening of 50,316 compounds 
was carried out with a Z’ score of 0.82 ± 0.05, and an outcome of 58 hits. After the 
structure analysis, three acridine analogues were unveiled and confirmed using the 
fluorescence polarization assay and the surface plasmon resonance assay. Moreover, 
a set of 17 additional acridine analogues was prepared and tested. Compound 
7 showed selectivity for Bcl-xL (KD = 6.5 μM) over Bcl-2 (KD = 160 μM) protein, and 
potent cytotoxicity (nanomolar scale) in PC-3, PC-3a and DU145 prostate cancer 
cells. Furthermore, induction of autophagy was also demonstrated in PC-3 and PC-3a 
cells treated with some acridine compounds by LC3 conversion immunoblotting and 
LC3 fluorescence microscopy. These Beclin 1 mimetics will be invaluable tools for 
developing novel autophagy inducers, better understanding the roles of autophagy 
in cancer, and will contribute to cancer therapy.
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Under certain circumstances, overactivation of autophagy 
can lead to autophagic cell death, or type II programmed 
cell death [6, 7]. In addition, most of the cellular systems 
where autophagy has been proven to contribute to cell 
death are defect in the apoptosis signaling pathways, as 
is the case in most tumors [8, 9]. Therefore, even though 
autophagy is most likely a pro-survival response in normal 
cell homeostasis, it might be a backup death program in 
apoptosis-resistant tumor cells [7, 9, 10]. If this hypothesis 
is correct, drugs that specifically trigger autophagic cell 
death should be well-tolerated due to highly specific 
killing of cancer cells. Moreover, autophagic cell death is a 
tempting way to circumvent apoptosis-resistance [11–13].
Autophagy is regulated by a set of conserved 
proteins, the autophagy-related (Atg) proteins [14]. 
Beclin 1, also named Atg6, is the first identified 
mammalian Atg protein and an essential autophagy inducer 
[15]. Beclin 1 forms a regulatory complex with class III 
phosphatidylinositol-3-kinase (class III PI3K or VPS34) 
that is important in the initiation of autophagy [16]. 
Beclin 1 is also a haploinsufficient tumor suppressor and 
mono-allelic deleted in 40%–75% human breast, ovarian 
and prostate cancer [15, 17]. Bcl-2 (B cell lymphoma 2) 
family proteins have been proposed as dual regulators of 
apoptosis and autophagy [18]. The anti-apoptotic Bcl-2 
homologs, Bcl-2 and Bcl-xL, can downregulate autophagy 
by interacting with the Beclin 1/class III PI3K complex, 
and sequestering Beclin 1 [16, 19, 20]. Beclin 1 carries 
one Bcl-2-homology-3 (BH3) domain, which is important 
for the Bcl-2-Beclin 1 interaction and required for Bcl-2-
mediated inhibition of autophagy [21, 22]. 
Several Bcl-2 inhibitors have been proven to 
competitively disrupt the interaction between Beclin 1 
and Bcl-2/xL, and induce autophagy. (–)-Gossypol is 
the first Bcl-2 inhibitor approved by FDA for clinical 
testing (AT-101) and has entered Phase II-IIb clinical 
trials (www.ClinicalTrials.gov). In our previous studies, 
we demonstrate that (–)-gossypol  preferentially induces 
autophagy in androgen-independent or castration-resistant 
prostate cancer cells that have high levels of Bcl-2 and are 
resistant to apoptosis, whereas apoptosis is preferentially 
induced in androgen-dependent cells with low Bcl-2 
[8]. (–)-Gossypol induces autophagy via blocking Bcl-
2-Beclin 1 interaction at the endoplasmic reticulum [8]. 
Moreover, the Bcl-2 inhibitor ABT-737 induces high 
levels of autophagy via binding to the BH3 binding 
groove of Bcl-2 or Bcl-xL (but not Mcl-1) and freeing out 
Beclin 1 [23–25]. ABT-737-induced autophagy cannot 
be inhibited by Bcl-2 or Bcl-xL overexpression, yet it is 
abolished by transfection with Mcl-1 or by the siRNA 
mediated knockdown of Beclin 1 [23, 26]. ABT-737 and 
its analogue ABT-263 (navitoclax) are in phase I/ phase II 
clinical trials [27]. 
In our previous screen for inhibitors of Bcl-2, we 
have discovered and synthesized a series of small molecule 
BH3-mimetics, including (–)-gossypol [8, 28]. We 
hypothesize that, in our original screening, we only focused 
on inhibitors of Bcl-2-Bax/Bak interaction that induce 
apoptosis, thus we may have missed some potential hits 
that more potently inhibit Bcl-2/xL-Beclin 1 interaction and 
induce autophagy instead of apoptosis. Here we report the 
discovery of several acridine compounds as small molecule 
Beclin 1 mimetics using the fluorescence polarization-
based (FP-based) high-throughput screening (HTS), the 
surface plasmon resonance (SPR) assay, and cell-based 
biological activity assays. The acridine compounds have 
inhibitory effects on the proliferation of prostate cancer 
cells and induce autophagy. These Beclin 1 mimetics 
represent promising leads to develop novel molecular 
therapy for human cancer with Bcl-2/xL overexpression 
and resistant to conventional chemo/radiotherapy.
RESULTS
FP-based HTS for Beclin 1 mimetics
To discover small molecule inhibitors of Bcl-xL-
Beclin 1 interaction, a sensitive, quantitative, in vitro 
FP-based binding assay was established and optimized 
for HTS. We first determined the proper Beclin 1 peptide 
for the FP assay. BH3 domain is necessary and sufficient 
for the interaction between Beclin 1 and Bcl-xL [22]. We 
therefore designed five fluorescein-labeled Beclin 1-BH3 
peptides with different length. They all contain the critical 
residues for the binding behavior (Figure 1A). A 16-mer 
(a 16 amino acid long peptide) Bak-BH3 peptide was used 
as a positive control [29]. As shown in Figure 1B, Bcl-
xL was titrated to a fixed solution of 50 nM fluorescent 
peptide and the changes of FP values were calculated. 
20-mer Beclin peptide, 26-mer Beclin peptide as well as 
Bak peptide exhibited good binding curves to Bcl-xL in 
this assay, while peptides of shorter sequence (e.g. 8-mer, 
10-mer and 12-mer) showed low or no binding affinity. 
Thus, we chose 20-mer, the shorter one of the two active 
peptides, as the binding peptide in the following FP assay. 
Buffer condition was then optimized (data not shown). 
Finally, 20-mer and Bak peptide was demonstrated to bind 
to Bcl-xL protein with equilibrium dissociation constants 
(Kd) of 969.5 nM and 33.92 nM, respectively (Figure 1B), 
which are sufficient for the following FP-based assays. 
Then, we set up a FP-based competitive binding inhibition 
experiment using 50 nM of fluorescent 20-mer and 2 µM 
of Bcl-xL (Figure 1C). Positive compounds, ABT-263 
[30, 31] and (–)-gossypol [12] are capable of freeing out 
fluorescent 20mer to experimental solution, and ABT-
263 is more potent than (–)-gossypol (Figure 1C). These 
results demonstrated that this FP competitive binding 
assay is suitable for identify small molecule inhibitors 
that can mimic Beclin 1 and abrogate Bcl-xL-Beclin 1 
interaction.
Next, we optimized the FP competitive binding 
assay in a 384-well microplate format and carried out a 
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small-scale HTS using a small library, which contains 
6580 compounds from Prestwick, Microsource and 
our in-house CMLD library. Then, the FP assay was 
optimized and applied in screening the larger Chembridge 
library consisting of 43736 compounds. The scattergrams 
of inhibitors activity are shown in Figure 1D–1E. HTS 
cascades are shown in Supplementary Figure 1A–
1B. According to the percent of inhibition, 68 active 
compounds (> median + 3SD) were selected as initial hits. 
After removal of autofluorescent and repeated compounds, 
41 hit compounds from the first screen (A01-A41) and 17 
hit compounds from the second screen (B01-B17) were 
chose for further studying, giving an overall hit rate of 
0.12% (Supplementary Table 1). The average Zʹ value 
was 0.82 ± 0.05 with a signal to background window of 
1.4, indicating a robust and reliable HTS assay (Figure 
1D–1E; Supplementary Figure 1C–1F). A complete list of 
the screening hits and the confirmatory data were listed 
in Supplementary Table 2–3 with PubChem Chemical ID 
(CID) number. All chemical structures can be found on 
the PubChem website (http://pubchem.ncbi.nlm.nih.gov/).
Structural similarity analysis of HTS hits
We employed a chemical structure clustering tool, a 
free online service from PubChem, to access the structure 
similarity of our hits. Tanimoto coefficient was used to 
quantify the structure similarity, which is by far the most 
popular and in widespread use today in computational 
medicinal chemistry [32]. Structural similarity clustering 
of 58 hits by a Tanimoto distance of 0.3 resulted in 29 
different clusters and singletons. Three major clusters were 
revealed (Figure 2). We found that some compounds in 
cluster I might be promiscuous, assay-duping molecules. 
They have the common structure of polyhydroxy 
naphthalene or anthraquinone, therefore can be considered 
as pan-assay interference compounds, or PAINS [33]. 
After carefully looking over the hit structures, three 
acridine analogues, A13, A15 and A21, from cluster II and 
cluster III were subjected to further analysis (Figure 2).
Validation of acridine compounds using two 
biochemical assays
We first validated the abilities of three acridine 
analogues to disrupt Bcl-xL-20-mer complex using the 
FP assay. As shown in Figure 3A, all three compounds 
exhibited potent and dose-dependent inhibitory effects in 
this assay (A13, Ki = 0.84 µM; A15, Ki = 28.04 µM; A21, 
Ki = 13.15 µM). 
Next, we developed a surface plasmon resonance 
assay to validate the binding activities of these compounds. 
SPR is a label-free, non-fluorescent biochemical assay that 
could assess the binding behavior directly. Bcl-xL protein 
was immobilized to the sensor surface, and analytes in 
solution were injected over the surface. As shown in Figure 
3B, compounds A13, A15, and A21 could bind to Bcl-xL 
at the concentration of 10 µM, and the SPR sensorgram 
displayed direct interactions between compounds and Bcl-
xL protein. For example, while A21 was injected over the 
surface, response unit (RU) increased rapidly, indicating a 
fast accumulation or binding of A21 on the surface; while 
A21 was diluted away by running buffer, RU decreased 
rapidly, indicating a fast dissociation of the complex. 
Obviously, A21 dissociated faster than the other two acridine 
compounds, indicating the different interactions between 
Bcl-xL and the acridine compounds (Figure 3B). Taken 
together, FP and SPR results confirmed that compounds 
A13, A15, and A21 could abrogate Bcl-xL-Beclin 1 
interaction through direct binding to Bcl-xL protein.
Acridine compounds inhibit cell growth and 
induce autophagy in human prostate cancer cells
Three acridine analogues, A13, A15, and A21, were 
further assessed in cell-based assays. They exhibited 
potent inhibitory effects on the growth of human prostate 
cancer cell lines PC-3, PC-3a and DU145 (Table 1; 
Figure 4A), which have high levels of Bcl-2 family 
proteins. Moreover, A15 and A21 exhibited higher 
cytotoxicity in PC-3 and PC-3a than in DU145 cells, while 
A13 showed similar cytotoxicity to all three types.
Next, we tested LC3 conversion by the 
immunoblotting in PC-3 and PC-3a prostate cancer 
cells. Conversion of LC3-I to LC3-II is widely accepted 
as a marker of autophagy [34]. Increased level of LC3-
II was observed in cells treated with A13, A15 or 
A21, demonstrating their abilities to induce autophagy 
(Figure 5A). Using a tandem fluorescent-tagged LC3, we 
monitored the autophagic flux levels in PC-3 and PC-3a 
cells. Because GFP (green fluorescent protein) signal is 
quenched at the low pH inside the lysosomes, while RFP 
(red fluorescent protein) is stable at low pH condition [35], 
this assay could detect autophagosomes (yellow puncta) 
and autolysosomes (red puncta) at the same time. As shown 
in Figure 5B, we observed many strong red puncta in PC-
3a and PC-3 cells transfected with RFP-GFP-LC3 and 
treated with compounds A13, A15, or A21 for 24 h. This 
result demonstrated the appearance of autolysosomes and 
the activation of autophagic flow in the cells. Based on the 
results of two cellular assays, we established the activation 
of autophagic process in PC-3 and PC-3a treated with 
compound A13, A15 or A21. These results are consistent 
with our design strategy that the compounds disrupting Bcl-
xL-Beclin 1 interaction could induce autophagy.
Structure-activity relationship (SAR) analysis of 
A21 derivatives
To test the activity of acridine structure and gain a 
primary SAR, we built a set of seventeen A21 analogues. 
According to their structures, these compounds were 
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divided into four groups (Figure 6A). Group I (1, 2, 4 and 
5) includes compounds with only one substitution at 9 
position of the acridine ring; group II (7–10 and 13–17) 
contains 6-chloro-2-methoxyacridines with different 
substitutions at 9 position; group III (11 and 12) consists 
of 2-methoxyacridines with different substitutions at 9 
position; and the acridine rings of compounds in group IV 
(3 and 6) were replaced by other heterocycles.
The binding affinity of these acridine analogues 
to Bcl-xL protein was determined using the SPR assay. 
Figure 6B showed that only compound 7 had higher 
binding level than original hit A21 at the concentration 
Figure 1: FP-based HTS for Beclin 1 mimetics. (A) Schematic presentation of the Beclin 1 protein and sequences of five synthetic 
peptides modified from Beclin 1 BH3 peptide. Diagram of human Beclin 1 protein with different domains is shown in the bottom. BH3 
domain is necessary and sufficient for interaction with Bcl-2/Bcl-xL. Amino acids in red are the critical residues for the binding. (B) Five 
fluorescein-labeled Beclin 1 BH3 peptides were tested for their binding ability to Bcl-xL protein in FP assay. Fluorescein-labeled Bak BH3 
peptide was used as a positive control. Bcl-xL protein was titrated to a solution of 50 nM peptides. (C) Competitive binding assay with 
positive controls, ABT-263 and (–)-gossypol ((–)G). Compounds were titrated to a solution of preformed 20-mer/Bcl-xL complexes. The 
concentration was 50 nM for 20-mer and 2 µM for Bcl-xL protein. (D–E) HTS was performed with ~50000 compounds from Prestwick, 
Microsource, CMLD and Chembridge libraries. The four libraries were divided into two groups and screened separately. Compounds 
activity (percent of inhibition) of first screen (D) and second screen (E) were shown with Zʹ value indicated on top. Plate median + 3SD was 
used as a threshold to determine the initial hits. 
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Figure 2: Structural similarity analysis of HTS hits. Left panel: based on the structure (fingerprint) similarity, 58 hits were sorted 
using a free online clustering tool from PubChem (http://pubchem.ncbi.nlm.nih.gov/). Single-linkage algorithm was used in the clustering, 
and a Tanimoto distance of 0.3 resulted in 29 different clusters and singletons (shown in white and grey). Compounds are listed by their CID 
number and code. Chemical structures can be found on the PubChem website, using their CID. Group I, II and III are three major clusters. 
Right panel: chemical structures of promising candidate compounds from cluster II and III. They contain a common structure of acridine. 
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of 10 µM, while compounds 1, 3, 6, 11, 14 and 15 had 
almost no binding to Bcl-xL. The results suggest that the 
acridine scaffold is essential for compounds to maintain 
their binding to target, as acridine-lacking group IV has 
the worst performance in this assay. Moreover, substituent 
group at the 9 position of acridine ring plays a significant 
role for the interaction between Bcl-xL and compound, 
as shown in different performance of compounds 1, 2, 4, 
5 and compounds 7, 8, 9, 10. To be specific, the amino 
substituent is better than alkyl group at 9 position, and 
secondary amine is preferred to tertiary amine for a 
higher affinity. In addition, we found the chloro group 
at 6 position has no effect on the binding ability, when 
compared the results of compounds 11 to 14, as well as 
12 to 13.
We also tested the cytotoxicity of the 17 compounds 
in human prostate cancer cell lines by MTT assay 
(Table 1). Compound 7 exhibited the most potent 
cytotoxicity against all three cell lines with IC50 values 
less than 0.5 µM (Figure 4B). Compound 5 also showed 
potent cytotoxicity with IC50 in between 0.5 µM and 5 
µM. However, compounds 3, 6, 11, 14 and 15 showed 
no cytotoxicity in this assay (IC50> 100 µM). Notably, 
compounds 5 and 7 displayed higher cytotoxicity in 
PC-3 and PC-3a cells than in DU145 cells (3–5 fold 
difference in IC50 value). In summary, cytotoxicity of most 
compounds correlate with their binding abilities to Bcl-xL 
protein, which indicate that these compounds may reduce 
the cell viability via disrupting an oncogenic pathway 
involving Bcl-2 family proteins.
Compound 7 selectively binds to Bcl-xL and 
induces autophagy
From the library of A21 derivatives, compound 7 
was identified with potent binding ability to Bcl-xL and 
cytotoxicity against prostate cancer cells (Figure 4B; 
Figure 6B). To gain a further insight into the interactions 
of compound 7 to Bcl-xL/2 protein, we used the SPR 
assay to test the binding affinity and kinetics. We found 
Figure 3: Validation of compounds A13, A15, and A21 binding to Bcl-xL protein. (A) Dose-response curves of acridine 
compounds disrupting Bcl-xL-20-mer complex in FP assay using 2.5 µM Bcl-xL protein and 400 nM fluorescein-labeled Beclin 1 BH3 
peptide (20-mer). (B) SPR sensorgram of acridine compounds confirmed their binding abilities to immobilized Bcl-xL protein at the 
concentration of 10 μM. Bcl-xL protein was immobilized on the sensor chip with 10000 RU. 
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Beclin 1 20-mer peptide and compound 7 have comparable 
binding affinity to immobilized Bcl-xL protein (KD = 7.3 
μM and KD = 6.5 μM, respectively; Figure 7A-7B). We 
also compared the binding behaviors of compound 7 
to the Bcl-xL with that to Bcl-2 protein. It showed that 
compound 7 has similar dissociated rates to these two 
proteins, but it associates faster to Bcl-xL than to Bcl-2, 
thus having a lower affinity to Bcl-2 protein 
(KD = 160.0 μM; Figure 7C–7D).
We next tested the effects of compound 7 on the 
autophagy pathway using western blotting. In addition to 
LC3 conversion, SQSTM1/P62 turnover can also be an 
important marker for assessing the autophagic flux [34]. 
Compound 7 triggered the conversion of LC3-I to LC3-
II and the degradation of P62 in PC-3 and PC-3a cells, 
indicating its ability to induce autophagy (Figure 8).
DISCUSSION
Here, we reported the efforts to screen and discover 
small molecule compounds mimicking the Beclin 1 
protein, a BH3-only protein and key inducer of autophagy. 
In FP-based HTS with 50,316 compounds, we identified 58 
initial hit compounds that block the interaction of Beclin 
1 20-mer to Bcl-xL protein. After structure similarity 
clustering, three acridine analogues, A13, A15 and A21, 
were subjected to further analysis. Their binding affinities 
were reconfirmed in both FP and SPR assay (A13, 
Ki= 0.84 µM; A15, Ki = 28.04 µM; A21, Ki = 13.15 µM). 
They showed potent anti-proliferative activity against 
prostate cancer cells (PC-3, PC-3a and DU145). They 
activated autophagic flux in PC-3 and PC-3a, determined 
by LC3 conversion and LC3 puncta assay. These acridine 
analogues represent a promising starting point for our 
SAR study. Thus, a small library of 17 acridine analogues 
has been set up and tested. Compound 7 was identified to 
bind to Bcl-xL (KD = 6.5 μM), inhibit cell growth (IC50 
< 0.5 µM against all three cells), and induce autophagy in 
PC-3 and PC-3a prostate cancer cells. Notably, compound 
7 has selectivity for Bcl-xL protein (about 25-fold over 
Bcl-2). These results validated our design hypothesis that 
Beclin 1 mimetics, compounds disrupting Bcl-xL-Beclin 
1 interaction, could induce autophagy and inhibit cell 
growth in apoptosis-deficient cancer cells. 
Autophagy and apoptosis are two prominent 
self-destructive processes that control the fate of cells. 
Generally the cell switches between the two responses 
in a mutually exclusive manner [36]. However, in some 
Table 1: MTT-based cytotoxicity assay of acridine derivatives
Compound
Cytotoxicity in different cell lines (IC50, μM)
DU145 PC-3a PC-3
A13 0.81 ± 0.51 0.68 ± 0.16 1.08 ± 0.10
A15 10.47 ± 1.11 2.33 ± 0.99 1.61 ± 0.42
A21 2.31 ± 0.39 0.80 ± 0.12 0.77 ± 0.10
1 8.15 ± 0.59 5.81 ± 1.16 6.04 ± 0.68
2 46.98 ± 7.39 29.20 ± 11.24 38.73 ± 5.46
3 > 100 82.66 ± 7.99 NT
4 6.33 ± 0.32 4.37 ± 0.68 4.43 ± 0.46
5 2.78 ± 0.79 0.74 ± 0.45 0.79 ± 0.07
6 > 100 > 100 > 100
7 0.27 ± 0.13 0.10 ± 0.05 0.11 ± 0.07
8 3.68 ± 0.55 1.64 ± 0.78 1.42 ± 0.73
9 6.24 ± 1.86 3.51 ± 1.15 2.93 ± 1.18
10 77.66 ± 24.17 36.09 ± 8.23 14.13 ± 0.71
11 > 100 > 100 > 100
12 45.44 ± 8.18 16.42 ± 2.56 21.56 ± 2.24
13 56.97 ± 14.45 53.86 ± 3.66 52.39 ± 10.36
14 > 100 > 100 > 100
15 > 100 > 100 > 100
16 35.99 ± 13.97 38.69 ± 20.42 44.96 ± 20.17
17 52.96 ± 14.71 > 100 29.49 ± 28.36
DU145, PC-3, and PC-3a: Human prostate cancer cell lines. Values are averages of at least two independent experiments. 
NT: Not tested.
Oncotarget51362www.impactjournals.com/oncotarget
cases, autophagy may help to active apoptosis, and 
excessively autophagy could even lead to autophagic 
cell death [4]. Early study showed that autophagy-
associated cell death can be seen as a backup cell 
death mechanism when apoptosis fails [8]. Bcl-2 
family proteins have been implicated in the regulation 
of both autophagy and apoptosis [27, 28, 37, 38]. 
The anti-apoptotic proteins from this family, such as 
Bcl-2, Bcl-xL or Mcl-1, could inhibit autophagy by 
binding to Beclin 1 [36]. Some pro-apoptotic BH3 
only proteins, such as Bad, Noxa, Puma, could active 
autophagy by blocking the interaction between Beclin 
1 and anti-apoptotic Bcl-2 family members. Moreover 
the C-terminus of cleaved Beclin 1 (Beclin 1-C) have 
a apoptosis-promoting function [39]. The Bcl-2/xL-
Beclin 1 interaction represents a intriguing molecular 
mechanism between the autophagy and apoptosis. We 
here focused on the Bcl-xL-Beclin 1 complex, and 
explored Beclin 1-mimicking agents that disrupt the 
complex and promote autophagy. However, the effects 
of our compounds on the apoptotic pathway are still 
uncertain and warrant further investigation.
Given that deficient autophagy is linked with a 
wide range of human diseases, many investigations 
are devoted to identify autophagy inducers [19, 35, 
40, 41]. Several available FDA-approved drugs have 
been repurposed for use in clinical indications, because 
of their autophagy-inducing activity [10, 42]. However, 
those drugs possess autophagy-inducing effects as well 
as other non-autophagy-inducing activities (side effects). 
The discovery and optimization of novel scaffolds, for 
maximal specificity and minimal side effect, is a major 
challenge in this field. The acridine structures we found in 
this study provided novel templates for further medicinal 
chemistry optimization. The primary SAR analysis of 
17 acridine analogues provided information for further 
structure-based modifications and lead optimization.
These Beclin 1 mimetics might be promising tools 
for understanding the roles of Bcl-xL protein, Beclin 
1, and even the multifaceted roles of autophagy in 
cancer development and drug resistance. In MTT-based 
cytotoxicity assay, PC-3a and PC-3 cells seem to be more 
responsive to the compounds than DU145 cells, potentially 
due to higher levels of Bcl-xL/2. As those compounds 
Figure 4: The growth inhibitory effects of several acridine compounds in vitro. (A) Compounds A13, A15, A21, and 5 inhibit 
PC-3 prostate cancer cell growth in a dose-dependent manner. (B) The cytotoxicity of compound 7 against DU145, PC-3a and PC-3 cancer 
cell lines.
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Figure 5: Acridine compounds induce autophagy in prostate cancer cells. (A) LC3-II conversion in western blot analysis 
indicated the activity of autophagy. Cells were treated with DMSO or compounds for 24 h, and then lysed and processed for western 
blot analysis of LC3. (–)G and EBSS were used as positive controls. (B) RFP-GFP-LC3 puncta (indicated by white arrows) in cells after 
treatment suggested the induction of autophagy. Yellow puncta indicate autophagosome (overlay of red and green fluorescence); red puncta 
indicate autolysosome (due to green fluorescence quenching at the acidic condition). Cells expressing RFP-GFP-LC3 were treated with 
compounds A13, A15 or A21 at indicated concentration for 24 h. 
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Figure 6: Analysis of structure-activity relationship of A21 derivatives. (A) The chemical structures of acridine derivatives. (B) 
The maximal binding levels of acridine analogues to Bcl-xL protein at a concentration of 10 µM were tested using SPR. The compounds 
showed different binding ability to Bcl-xL protein.
Figure 7: SPR analysis of compound 7. (A, B, C) SPR binding curves, or sensorgrams, for Beclin 20-mer peptide to immobilized 
Bcl-xL (A), compound 7 to Bcl-xL (B) and compound 7 to Bcl-2 (C). Sensorgrams representing direct binding kinetics for analytes are 
shown in response unit (RU) as a function of time (second) with increasing concentration (0.016–10 µM for 7; 1–25 µM for 20-mer). (D) 
The association rate (Ka), dissociation rate (Kd) and equilibrium dissociation constant (KD) were listed. KD was determined by Kd/Ka. 
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have been proven to bind to Bcl-xL (7 has selectivity for 
Bcl-xL), PC-3a and PC-3 cells are more likely to rely upon 
Bcl-xL for its sustained growth.
Taken together, through our HTS effort and 
following structural, biochemical, and cellular evaluations, 
we have identified four potential Beclin 1 mimetics, A13, 
A15, A21 and 7. They have high binding affinity to Bcl-
xL, kill prostate cancer cells via disrupting a Bcl-xL-
related oncogenic pathway and activate autophagic flux in 
prostate cancer cells. These Beclin 1 mimetics represent 
new templates warranting further medicinal chemistry 
optimization. Furthermore, these compounds will be good 
tools for exploring the roles of Bcl-xL in malignant tumor 
cells and investigating the potential of autophagy to kill 
cancer cells. Future plan includes design and synthesis of 
novel acridine-based Beclin 1 mimetics for high potency 
and selectivity. Moreover, future experiments will focus 
on exploring target effectiveness, target specificity and 
mechanism of action studies with the ultimate goal of 
developing novel small molecule Beclin 1 mimetics 
modulating autophagy for clinical benefits.
MATERIALS AND METHODS
Cell culture and reagents
Human prostate cancer cell lines PC-3 and 
DU145, were purchased from American Type Culture 
Collection (ATCC) and used within 50 passages. PC-
3a is a derivative of PC-3 that is resistant to chemo/
radiotherapy, established in our lab and confirmed 
by genotyping. All cells were maintained in DMEM 
(Mediatech, Manassas, VA) supplemented with 10% fetal 
bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), 1% 
Glutamine (Mediatech, Manassas, VA), 1% antibiotics 
(Mediatech, Manassas, VA). Compounds for primary FP-
based HTS screening were from Prestwick, Microsource, 
University of Kansas Center of Excellence in Chemical 
Methodologies & Library Development (KU CMLD, 
Lawrence, KS), and Chembridge libraries. Compounds for 
MTT and SPR validation experiment were purchased from 
Microsource (Gaylordsville, CT) and Hit2lead Company 
(San Diego, CA). Acridine analogues, compound 1–6, 
Figure 8: Acridine compounds induce autophagy in PC-3 and PC-3a cancer cells. LC3-II conversion in western blot analysis 
indicated the activity of autophagy. Cells were treated with DMSO or compounds for 24 h, and then lysed and processed for western blot 
analysis of LC3. (–)G and EBSS were used as positive controls. 
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were from our in-house library (provided by Specialized 
Chemistry Center, University of Kansas, Lawrence, 
KS); compound 7–17 were synthesized as described in 
supplementary information. (–)-Gossypol was isolated 
from racemic gossypol as we previously described [8, 43]. 
ABT-263 and DMSO were purchased from Sigma. MTT-
based cytotoxicity assay and western blot analysis was 
carried out according to our previous publications [44]. 
The primary antibodies used were LC3B (#2775) (Cell 
signaling Technology, Danvers, MA) and β-actin (A5441) 
(Sigma). 
Fluorescence polarization assay 
All Nʹ-fluorescein-labeled peptides were purchased 
from Kansas State University (Manhattan, KS). Beclin 1 
8-mer, 10-mer, 12-mer, 20-mer and 26-mer peptides were 
designed in our lab. 16mer Bak (GQVGRQLAIIGDDINR) 
sequence was from published literature [29, 45]. Bcl-
xL protein (25 kDa, > 90% pure based on SDS–PAGE) 
was expressed and purified in Protein Product Group, 
University of Kansas. FP assays were carried out as 
described in our previous publication [44, 46] with some 
modified. For the assay optimization and determination of 
equilibrium dissociation constant (Kd), purified proteins 
were serially diluted in binding buffer (20 mM HEPES, 
pH 7.4, 0.05% pluronic F-68), and added to 96-well 
assay plates (Corning 3915) (Corning, Corning, NY). 
Then, fluorescein-labeled peptide was added to each 
well with a final concentration of 50 nM and incubated at 
room temperature for 30 min. Anisotropy measurements 
were taken at room temperature using a BioTek Synergy 
H4 plate reader (Biotek, Winooski, VT) following the 
protocol recommended by the manufacture. The Kd was 
estimated by nonlinear regression to a one-site binding 
model using GraphPad Prism 5.0 (GraphPad, San Diego, 
CA). For competitive binding experiment, compound in 
serial dilutions (1 nM to 100 µM) was added to Bcl-xL-
Beclin 1 20-mer complex in the assay buffer in a 96-well 
black microplate. The final concentrations of Bcl-xL and 
20-mer were 2 µM and 50 nM, respectively. Compound 
solvent DMSO only was used as a negative control in the 
competition assay. After 2 h incubation, the plate was read 
and polarization was calculated.
FP-based high-throughput screening
To form the Bcl-xL-Beclin 1 complex, Bcl-xL 
was incubated with Beclin 1 20-mer in binding buffer 
(20 mM HEPES, pH 7.4, 0.05% Pluronic F-68) for 5 min 
at 25°C. Forty microliter aliquots of the mixture were 
added to the 384-well plates containing the compounds 
(for a final concentration of 2.5 µM Bcl-xL, 400 nM 
20-mer, and 40 µM compounds in the first screen; 
and a final concentration of 2.5 µM Bcl-xL, 300 nM 
20-mer, and 30 µM compounds in the second screen) and 
further incubated at 25°C for 2 h. Then the plates were 
read by Envision (Perkin Elmer, Waltham, MA). The 
compounds with an inhibition of greater than plate median 
plus 3 standard deviation were selected as hits. The hits 
were selected from library stocks and reconfirmed in a 
concentration response FP assay (6 doses ranging from 
5 µM to 160 µM or 8 doses ranging from 0.5 µM to 
60 µM). The percent of inhibition was normalized such that 
the FP value of the protein-peptide complex with DMSO 
was defined as 0% inhibition, while the FP value obtained 
with the same concentration of the free fluorescein-labeled 
20-mer alone was defined as 100% inhibition.
Surface plasmon resonance assay 
The surface plasmon resonance experiments 
were performed using a Biacore 3000 (GE Healthcare 
Pittsburgh, PA) equipped with a research-grade CM5 
sensor chip. The ligand (Bcl-xL) was immobilized using 
amine-coupling chemistry. The surfaces of flow cells on 
a Biacore sensor chip CM5 were activated for 7 min with 
a 1:1 mixture of 0.1 M NHS (N-hydroxysuccinimide) 
and 0.1 M EDC (3-(N,N-dimethylamino) propyl-N-
ethylcarbodiimide) at a flow rate of 5 μL/min. The ligand 
(Bcl-xL) at a concentration of 180 μg/mL in 10 mM 
sodium acetate, pH 4.5, was immobilized at a density 
of about 10000 RU on flow cell 2; the ligand (SUMO-
Bcl-2, 37.5 kDa, > 90% pure based on SDS–PAGE) at a 
concentration of 44 μg/ml in 10 mM sodium acetate, pH 
4.5, was immobilized at a density of 10000 RU on flow 
cell 3; flow cell 1 was left blank to serve as a reference 
surface. All the surfaces were blocked with a 7 min 
injection of 1 M ethanolamine, pH 8.0. 
For kinetic analysis, a concentration series of 
analyte were injected over the flow cells at a flow rate of 
60 μL/min at 20 °C. The complex was allowed to associate 
and dissociate for 120 and 180 s, respectively. For binding 
studies, analyte (or test compound) was injected over the 
two flow cells in duplicate at indicated concentration at 
a flow rate of 60 μL/min at 20 °C. The running buffer 
consisted of 20 mM HEPES, 150 mM NaCl, 3 mM EDTA, 
1 mM DTT, 0.05% P20, 5% DMSO, pH 7.4. The complex 
was allowed to associate and dissociate for 120 and 180 
s, respectively. The buffer samples containing a range of 
4–6% DMSO were injected at the beginning, used for 
solvent correction. The surfaces were regenerated between 
binding cycles with a 5 s injection of 5 mM NaOH for 
compounds and 10 mM Glycine pH 2.5 for 20-mer. 
All measurements were taken with flow cell 1 as 
a reference (i.e. sensorgram depicts “2–1 correction”) 
and corrected for DMSO bulk differences via the 
calibration curves. To obtain kinetic rate constants (Ka 
and Kd), corrected response data were fit to a simple 1:1 
interaction model using local fit (includes correction for 
mass transport limitations) available within Biaevaluation 
3.1 software or Scrubber2 software. The equilibrium 
dissociation constant (KD) was determined by Kd/Ka.
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GFP-RFP-LC3 analysis
PC-3 and PC-3a cells were transfected with ptfLC3 
plasmid using Lipofectamine 2000 (Invitrogen Life 
Technologies, Carlsbad, CA). ptfLC3 was a gift from 
Tamotsu Yoshimori (Addgene plasmid # 21074) [47], and 
is a tandem fluorescent-tagged LC3 with mRFP (mRFP, 
monomeric Red Fluorescent Protein) and EGFP (EGFP, 
Enhanced Green Fluorescent Protein). Twenty-four hours 
after transfection, cells were treated with compounds for 
24 h, then fixed in 4% formaldehyde for 10 min. Cells 
were then washed three times with PBS, stained with 
DAPI (0.5 µg/ml in PBS) for 5 min and observed under a 
fluorescence microscope (OLYMPUS IX81, Tokyo, Japan) 
with X 40 lens.
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